Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Personalized Breast Cancer Vaccines Based on Genome Sequencing

ABSTRACT: Personalized Breast Cancer Vaccines Based on Genome Sequencing

PROVIDER: PRJNA801392 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Personalized Breast Cancer Vaccines Based on Genome Sequencing

Project description:Personalized Breast Cancer Vaccines Based on Genome Sequencing

| PRJNA801393 | ENA

Iimmunopeptidomics pipeline for generation of personalized oncolytic cancer vaccines.

Project description:We used a streamlined pipeline for the generation of personalized cancer vaccines starting from the isolation and selection of the most immunogenic peptide candidates expressed on the tumour cells and ending in the generation of efficient therapeutic oncolytic cancer vaccines. We used MHC-I immunoaffinity purification in a murine colon tumor model from CT26 cells. The selection of the target candidates was then based on two separate approaches: RNAseq analysis and HEX software.

2022-04-06 | PXD026463 | Pride

Engineering irradiated tumor-derivedmicroparticles as personalized vaccines toenhance antitumor immunity

Project description:Engineering irradiated tumor-derivedmicroparticles as personalized vaccines toenhance antitumor immunity

| PRJNA1000457 | ENA

Engineering irradiated tumor-derivedmicroparticles as personalized vaccines toenhance antitumor immunity

Project description:The inadequate activation of antigen-presenting cells, the entanglement of T cells, and the highly immunosuppressive conditions in the tumor microenvironment (TME) are important factors that limit the effect of cancer vaccines. Studies have shown that individualized and broad antigens can fully activate anti-tumor immunity and inhibiting the function of TGF-β can facilitate T cell migration to tumor sites. Based on our previous study, we introduced a new vaccine strategy by engineering irradiated tumor cell-derived microparticles (RT-MPs), which have both individualized and broad antigens, to induce broad antitumor effects and cause immunogenic death. Encouraged by the proinflammatory effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the high affinity between TGF-βR2 and TGF-β, we developed RT-MPs with the SARS-CoV-2 spike protein and TGF-βR2. We found that this spike protein and high TGF-βR2 expression induces the innate immune response and ameliorates the immunosuppressive TME, thereby promoting T cell activation and infiltration, and ultimately inhibiting tumor growth. In addition, when combined with anti-programmed death 1 (anti-PD-1) the engineered RT-MPs were able to generate an immune memory response and eliminate subcutaneous tumors. Our study provides a novel strategy for producing an effective personalized anti-tumor vaccine for clinical application.

2023-10-27 | GSE239631 | GEO

Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance antitumor immunity

Project description:Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance antitumor immunity

| PRJNA1002297 | ENA

Human iPSC-based personalized cell therapy of PD

Project description:Human iPSC-based personalized cell therapy of PD

| PRJNA1118835 | ENA

Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance antitumor immunity

2023-10-27 | GSE240108 | GEO

Oral administration of engineered yeast produced H5HA-based vaccines

Project description:H5N8 influenza virus is a highly pathogenic pathogen for the poultry and human. Vaccination is the most effective method to control the spread of the virus right now. The traditional inactivated vaccine, though well developed and used widely, is laborious during application and more interests are stimulated in developing alternative approaches. In this study, we developed three HA gene-based yeast vaccines and our experimental results demonstrated that all of these vaccines elicited the humoral immunity, inhibited viral load in the chicken tissues, and provided protective efficacy partially due to the high dose of H5N8 virus. Molecular mechanism studies suggested that, compared to the traditional inactivated vaccine, our engineered yeast vaccines reshaped the immune cell microenvironment in bursa of Fabriciu to promote the defense and immune responses. Analysis of gut microbiota further suggested that oral administration of engineered ST1814G/H5HA yeast vaccines increased the diversity of gut microbiota and the increasement of Reuteri and Muciniphila might benefit the recovery from influenza virus infection. These results provide strong evidences for further clinical use of these engineered yeast vaccines in poultry.

2023-01-01 | GSE220714 | GEO

Oral administration of engineered yeast produced H5HA-based vaccines

Project description:Oral administration of engineered yeast produced H5HA-based vaccines

| PRJNA911230 | ENA

circRNA vaccines

Project description:circRNA vaccines

| PRJNA912726 | ENA